National Institute of Arthritis and Musculoskeletal and Skin Disease (NIAMS)

Search Our Work by NIH Institute/Center

Partnerships with this Institute

Key Initiatives, Research Partners

This groundbreaking initiative expands the science of targeted medicine. The study of biomarkers creates the potential to individualize medical treatment by determining how a drug works in the body and identifying patients likely to respond to targeted medicines and therapies.

Completed Programs, Program

The most common type of arthritis, osteoarthritis affects over 15 million people in the United States. Working in collaboration, the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute on Aging (NIA), the and the private sector are striving to improve the efficiency of drug development and clinical trials for the treatment of osteoarthritis.

Completed Programs, Program

Osteoarthritis—the most common form of arthritis—is a degenerative joint disease, and the major cause of physical limitations and disability in older people. Today, 35 million people (13 percent of the U.S. population) are 65 and older, and more than half of them have clear evidence of osteoarthritis in at least one joint. By 2030, 20 percent of Americans (about 70 million people) will have passed their 65th birthday and will be at risk for osteoarthritis.